Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

A kind of technology of anectostat acetate and correlation, applied in the direction of organic active ingredients, medical preparations containing active ingredients, steroids, etc.

Inactive Publication Date: 2005-09-28
ALCON INC
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this treatment has been shown to delay rather than terminate vision loss in the majority of patients treated (2)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
  • Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
  • Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] Anacorta acetate (4,9(11)-pregnane-17α,21-diol-3,20-dione-21 acetate) is currently being exuded in this ongoing multicenter trial Clinical evaluation of monotherapy for subfoveal AMD. The results of an interim analysis of safety and efficacy clinical data for the first 6 months after a single dose of the drug are reported here.

[0017] This ongoing trial was initiated to compare the clinical efficacy of anecortax acetate versus placebo treatment for vision preservation (maintenance) and inhibition of CNV lesion progression. The trial enrolled primary or recurrent subfoveal choroidal neovascularization (CNV) lesions up to 30.48 mm in size with a logMAR visual acuity of 0.3 (equivalent to 20 / 40 Snellen) to 1.2 (equivalent to 20 / 320 Snellen) secondary to AMD 2 (12 panel areas) for patients. The inclusion and exclusion criteria of this study are listed in Table 1. Best-corrected logMAR visual acuity was obtained for all patients at baseline and follow-up visits using gu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.

Description

[0001] This application claims priority to U.S.S.N 60 / 401,220, filed August 5,2002. [0002] The present invention relates to the use of anecortamate acetate for maintaining vision and providing vision protection in age-related macular degeneration (AMD) patients. Background of the invention [0003] AMD is currently the leading cause of functional blindness in patients over the age of 50 in developed countries. Although the exudative form is present in only 15-20% of the AMD population, exudative AMD accounts for the majority of significant vision loss (1). Until recently, the only approved treatment for CNV associated with exudative AMD was laser photocoagulation. In 2000, photodynamic therapy with Visudyne(R) was approved as a treatment for selected subfoveal lesions in this patient population. However, it has been shown that this treatment only delays rather than terminates vision loss in the majority of patients treated (2). [0004] Because the irreversible retinal da...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/573A61K9/00A61K31/00A61K31/56A61P27/02C07J5/00
CPCA61K31/57A61K9/0024A61K31/56A61P27/00A61P27/02A61P27/06
Inventor J·A·耶丹P·奇利奥克斯S·M·罗伯特松
Owner ALCON INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com